

THROMBOSIS AND HEMOSTASIS

Solution structure of the major factor VIII binding region on von Willebrand factor

Nuha Shiltagh,¹ John Kirkpatrick,¹ Lisa D. Cabrita,¹ Tom A. J. McKinnon,² Konstantinos Thalassinos,¹ Edward G. D. Tuddenham,^{1,3} and D. Flemming Hansen¹

¹Division of Biosciences, Institute of Structural and Molecular Biology, University College London, London, United Kingdom; ²Department of Haematology, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom; and ³Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Hospital NHS Trust, London, United Kingdom

Key Points

- The high-resolution structure of the complex disulfide-bonded TIL'E' (D') region of VWF is presented.
- The major factor VIII binding site is localized around a flexible region on the TIL' domain.

Although much of the function of von Willebrand factor (VWF) has been revealed, detailed insight into the molecular structure that enables VWF to orchestrate hemostatic processes, in particular factor VIII (FVIII) binding and stabilization in plasma, is lacking. Here, we present the high-resolution solution structure and structural dynamics of the D' region of VWF, which constitutes the major FVIII binding site. D' consists of 2 domains, trypsin-inhibitor-like (TIL') and E', of which the TIL' domain lacks extensive secondary structure, is strikingly dynamic and harbors a cluster of pathological mutations leading to decreased FVIII binding affinity (type 2N von Willebrand disease [VWD]). This indicates that the backbone malleability of TIL' is important for its biological activity. The principal FVIII binding site is localized to a flexible, positively charged region on TIL', which is supported by the rigid scaffold of the TIL' and E' domain β sheets. Furthermore, surface-charge mapping of the TIL'E' structure reveals a potential mechanism for the electrostatically guided, high-affinity VWF·FVIII interaction. Our findings provide novel insights into VWF·FVIII complex formation, leading to a greater understanding of the molecular basis of the bleeding diathesis type 2N VWD. (*Blood*. 2014;123(26):4143-4151)

Introduction

The preservation of hemostatic integrity is secured by the activities of von Willebrand factor (VWF). Upon vascular damage, VWF acts as a molecular bridge facilitating the initial adhesion and aggregation of platelets to the site of vessel injury. Furthermore, VWF is the protective carrier of procoagulant factor VIII (FVIII) in plasma, thereby prolonging its half-life and efficiently localizing FVIII to the incipient platelet plug.^{1,2} The arrest of bleeding is critically dependent on VWF, as exemplified by von Willebrand disease (VWD), the most common inherited bleeding disorder in humans, which results from defective or deficient VWF protein.³

The importance of VWF·FVIII complex formation is illustrated by patients with severe VWD, who have undetectable VWF levels. Not only do these patients have a concomitant deficiency of FVIII, but they also have a considerably shortened survival of intravenously administered FVIII.¹ This phenotype, which mimics hemophilia A, is also observed in patients with type 2N VWD, whose VWF harbors mutations that lead to decreased FVIII binding affinity.⁴ This behavior reflects the dependence of FVIII survival on the formation of VWF·FVIII complexes and illustrates the biological

significance of this interaction. Hence, the importance of elucidating the structure of the FVIII binding region on VWF is 2-fold. First, it would provide insights into the mechanism of FVIII binding to VWF and reveal the minimal VWF unit required to stabilize FVIII. Second, analysis of VWD patient mutations against a background of both structural and functional perturbations will provide the link between genetic pathology and clinical phenotype.

Electron microscopy studies have given a first glimpse of the domain arrangement and overall structure of the multidomain VWF protein⁵ and in particular showed that the trypsin-inhibitor-like (TIL') E' domains form a protrusion from the D3 domain, thereby presenting the TIL'E' domains to the physiological binding partner FVIII. However, the limited resolution of these structures has precluded the elucidation of the details needed to examine the molecular recognition and binding of FVIII to VWF. In addition, high-resolution structure determinations of the topologically complex disulfide-bonded VWF domains have not hitherto been feasible, except for the triplicated A domains,^{6,7} which are notable for their

Submitted July 25, 2013; accepted March 18, 2014. Prepublished online as *Blood* First Edition paper, April 3, 2014; DOI 10.1182/blood-2013-07-517086.

Presented as an oral communication at the XXIV congress of the International Society on Thrombosis and Haemostasis, Amsterdam, the Netherlands, July 1, 2013.

The atomic coordinates have been deposited in the Protein Data Bank (<http://www.pdb.org>) with the accession numbers 2mhp (single structure) and 2mhq (ensemble), and the chemical-shift assignments have been deposited in the

Biological Magnetic Resonance Data Bank (<http://www.bmrb.wisc.edu>) with the code 19646.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2014 by The American Society of Hematology

TIL'




Figure 1. Major FVIII binding sequence on VWF. The amino-terminal 99 residues (residues 766-864) of the mature VWF protein comprise the TIL' and E' domains, which form the basis of this paper. Positionally conserved cysteine residues are highlighted in black and numbered sequentially. Yellow lines show disulfide connectivities, and an asterisk marks connectivities that have been previously chemically assigned. The circled Cys846-863 (2-6) disulfide connectivity of the E' domain is assigned in this study. Type 2N VWD mutations are shown with arrows directly under the sequence together with the 1-letter code of the mutation; type 2N mutations involving a cysteine residue are in black, and non-cysteine mutations are in green. Secondary structure elements (arrow, β sheet, line, loop; spiral, 3_{10} helix) are shown under the sequence.

relative scarcity of cysteine residues. Thus, a detailed characterization of the interaction between VWF and FVIII has remained intractable, until now.

The FVIII binding region on VWF has been identified within a tryptic fragment termed SPIII-T4 (residues 767-1031).⁸ A recent domain assignment of VWF, based on conserved cysteine signatures,⁹ reveals that SPIII-T4 is composed of 3 distinct and conserved domains, namely TIL' (residues 766-827), E' (residues 829-863), and VWD3 (residues 867-1031). Accumulated lines of evidence suggest that of these regions it is the TIL' and E' domains (Figure 1), previously known collectively as D', that are essential for FVIII binding.³ First, 72% of unique missense mutations that directly affect FVIII binding to VWF (type 2N VWD) are found in domains TIL' and E'.¹⁰ Importantly, the most severe type 2N phenotypes, characterized by the lowest circulating plasma FVIII levels, are due to mutations in TIL' (Figure 1 and supplemental Figure 1 available on the *Blood* Web site).⁴ Second, epitope-mapping studies of potent FVIII binding-blocking monoclonal antibodies (mAbs) mAb-418 (VWF epitope, residues 765-816) and mAb-32B12 (VWF epitope, residues 814-821) indicate that the putative FVIII binding site is localized to TIL'.^{11,12}

Here, we present the solution structure and a characterization of the structural dynamics of the TIL' and E' domains of VWF. The TIL'/E' structure and dynamics provide an unprecedented view of the FVIII binding site on VWF and reveal a potential mechanism for the electrostatically guided VWF-FVIII interaction.

Materials and methods

Protein expression

The TIL'/E' coding sequence (residues 766-864) was amplified from full-length VWF complementary DNA and cloned into a pET32b+ vector containing an N-terminal thioredoxin (TRX) and His₆ tag. The TRX-His₆ tag was separated from the TIL'/E' coding sequence by a 31-residue linker (SSGLVPRGSGMKETAAAKFERQHMDSPDLGT) and a tobacco etch virus (TEV) cleavage sequence (ENLYFQ↓G), leaving residues GAMG as cloning artifacts. Constructs of TIL'/E' were expressed in *Escherichia coli* SHuffle cells¹³ and grown in ~4 L of either lysogeny broth or M9 minimal medium. Isotope-labeled samples were grown in M9 minimal medium supplemented with 2.5 g/L ¹³C-glucose (uniform [U]-¹³C labeling) and 1 g/L ¹⁵NH₄Cl (U-¹⁵N labeling) as the sole sources of carbon and nitrogen, respectively. For the 10% fractionally ¹³C-labeled TIL'/E' used for stereospecific assignment of the Val and Leu side-chain methyl groups, the M9 medium was

supplemented with 10% U-¹³C-glucose and 90% unlabeled glucose. Cells were grown to an optical density (OD) at 600 nm of ~0.6, and subsequent overexpression for 16 hours at 16°C was induced by the addition of 0.4 mM isopropyl-beta-D-thiogalactopyranoside.

Protein purification

After harvesting, the cells were resuspended in ~40 mL of wash buffer (20 mM sodium phosphate, 500 mM NaCl, 40 mM imidazole [pH 7.4]). To the cell suspension was added 1 tablet of Complete Protease Inhibitor (Roche), nonionic and nondenaturing detergent in the form of 0.25% octylphenyl-polyethylene glycol, lysozyme, and DNase (5-10 μ g/mL). Cells were broken by French press and subsequently centrifuged, and the cleared lysate (~40 mL) was filtered (0.22 μ m) and loaded onto a His-Trap Nitrilotriacetic acid column (5 mL; GE Healthcare) pre-equilibrated with wash buffer. Bound protein was eluted using a linear gradient with increasing imidazole and pooled fractions dialyzed against 20 mM sodium phosphate, 100 mM NaCl (pH 7.4) for TEV proteolysis. TEV protease was added in the ratio of 1 OD₂₈₀ unit TEV per 5 to 10 OD₂₈₀ units of TRX-His₆-TIL'/E'; the reaction was incubated for 3 hours at room temperature and then at 4°C overnight to complete cleavage. Subsequently, the N-terminal TRX-His₆ tag was separated from the cleaved TIL'/E' fraction on the His-Trap nitrilotriacetic acid column. The TIL'/E' was loaded onto a 16/60 Superdex 75 column (GE Healthcare) pre-equilibrated with 20 mM sodium phosphate, 100 mM NaCl (pH 7.4) as a final purification step. Monomeric TIL'/E' was concentrated to 450 μ L with final sample concentrations of 0.2 to 0.4 mM for further analyses.

Isotope-labeled ¹⁵N and ¹³C,¹⁵N samples were prepared in 20 mM sodium phosphate, 100 mM NaCl, 10% D₂O at pH 7.4 for nuclear magnetic resonance (NMR) spectroscopy. Samples used for backbone residual dipolar coupling (RDC) measurements were prepared by adding Pf1 bacteriophage (ASLA Biotech, Latvia)¹⁴ (~5 mg/mL) or pentaethylene glycol dodecyl ether (C₁₂E₅)/*n*-hexanol (Sigma-Aldrich) (3% wt/wt C₁₂E₅, *r* = 0.94),¹⁵ where *r* is the molar ratio of C₁₂E₅ to *n*-hexanol, with corresponding deuterium quadrupolar splittings in Pf1 and C₁₂E₅/*n*-hexanol of ~1.5 Hz and 8 Hz, respectively.

Mass spectrometry

Recombinant TIL'/E' (10 μ M) was buffer exchanged into 100 mM ammonium acetate (pH 7.0) for mass spectrometry (MS) experiments, which were carried out on a Synapt HDMS (Waters) mass spectrometer.¹⁶ A 2.5- μ L aliquot of the protein sample was delivered to the mass spectrometer by means of nanoelectrospray ionization using gold-coated capillaries (prepared in-house).

Ellman's reagents

Formation of all disulfide bonds was verified by an Ellman's assay with 5,5'-dithio-bis-(2-nitrobenzoic acid) which reacts with a free sulfhydryl group to




Figure 3. Binding analysis of TIL'E' functionality. Solid-phase binding assays of recombinant FVIII to plasma-derived VWF (pdVWF; ▼), TIL'E' expressed in *E. coli* (TIL'E'; ■), and reduced and alkylated TIL'E' (Red./alkyl. TIL'E'; ●). The obtained apparent dissociation constants are pdVWF 0.9 nM \pm 0.2 nM and TIL'E' 26 nM \pm 2 nM.

conformation. Solid-phase binding assays²⁴ of the TIL'E'-FVIII interaction were undertaken to establish biological activity (Figure 3). Analysis of the binding assays showed that TIL'E' binds to recombinant FVIII with an apparent affinity of 26 nM \pm 2 nM, which is similar to the binding affinity of the SPIII-T4 fragment to FVIII (50-80 nM^{25,26}). Reduced and alkylated TIL'E' does not bind to FVIII, showing that the binding observed for TIL'E' is due to specific rather than unspecific binding. Moreover, the binding affinity of the nonglycosylated TIL'E' construct is at least as strong as the binding affinity of the slightly larger SPIII-T4 construct, demonstrating that glycosylation of TIL'E' is not required for the specific TIL'E'-FVIII interaction. Using the same experimental setup, we also determined the binding affinity of plasma-derived VWF to FVIII, $K_d = 0.9$ nM, which is in the range of previously obtained results (eg, 0.52 nM,²⁵ 1.5 nM²⁷), thus validating our result for recombinant TIL'E'. Binding of TIL'E' to the conformation-dependent, FVIII binding-blocking VWF mAb-418 further confirmed the presence of a FVIII binding site on TIL'E' (supplemental Figure 4). Overall, the binding experiments performed suggest that the recombinantly produced TIL'E' is a faithful representation of these domains in full-length VWF and retains their biological function. Importantly, the binding of TIL'E' to FVIII shown in Figure 3 identifies TIL' and E' as the domains of VWF that contribute the majority of the VWF-FVIII binding free energy.

NMR assignments, verification of disulfide-bond topology, and structure of the TIL'E' domains

After establishing that the recombinantly produced TIL'E' was both correctly folded and functional, the NMR resonances covering 78% of the TIL'E' ¹H, ¹³C, and ¹⁵N backbone nuclei were assigned using standard triple-resonance NMR experiments (Figure 2). The unassigned nuclei are predominantly located between residues 781 and 805 of the TIL' domain (supplemental Figure 5), a consequence of resonance broadening due to micro-to-millisecond chemical exchange processes in this region of the protein (see below). The resonances of side-chain ¹H and ¹³C nuclei were subsequently assigned using 3-dimensional carbon total correlated spectroscopy (CC-TOCSY)-based experiments to correlate the backbone resonances with those of the side chains,²⁸⁻³⁰ giving a total assignment of 89% of the TIL'E' nuclei. ¹⁵N- and ¹³C-edited NOE spectroscopy experiments were used to obtain 954 unique interresidue distance restraints

(supplemental Table 1; supplemental Figure 6) for structure determination. In addition, 108 backbone dihedral-angle restraints (supplemental Table 2) were derived from the TIL'E' chemical shifts,³¹ and 361 vector-orientation restraints were collected by measurement of multiple RDCs in 2 alignment media (supplemental Table 3).³²

The disulfide-bonding pattern shown in Figure 1 was verified by cross-disulfide NOEs corresponding to Cys_{*i*}-Cys_{*j*}, H ^{α/β} -Cys_{*i*}, H ^{α/β} , where Cys_{*i*}-Cys_{*j*} represents a predicted disulfide bond between the *i*th and *j*th cysteine residues in the domain sequence (supplemental Figure 7). This permitted the unambiguous assignment of 4 disulfide bridges, including Cys792-Cys827 in TIL' and Cys829-Cys851, Cys849-Cys858, and Cys846-Cys863 in E' that had been predicted⁹ but not previously biochemically assigned (Figure 1 and supplemental Figure 7). The overall disulfide-bonding topology was further confirmed by exclusion of the corresponding constraints from preliminary structure calculations. With the exception of the Cys788-Cys799 linkage and to some extent the Cys776-Cys804 linkage in the TIL' domain, which were poorly defined due to limited NOE density, all predicted cysteine pairs came into close proximity. Therefore, all disulfide bonds were included as constraints in the structure calculation, resulting in the solution structure of VWF TIL'E' shown in Figure 4.

TIL' has a long dominating loop, whereas E' is all β sheet

The global fold of TIL'E' shown in Figure 4 is crescent shaped, as has been suggested from electron microscopy imaging.⁵ The structure clearly shows that TIL' and E' form independently folding domains, confirming the previous domain assignment separating D' into the 2 distinct domains.⁹ Salient features of domain TIL' (residues 766-827) are the limited regions of secondary structure (~70% loop; 26%




Figure 4. High-resolution solution structure of VWF TIL'E'. Ribbon diagram of the lowest-energy solution structure of TIL'E' of VWF; disulfide bonds are colored yellow. The TIL' domain (bottom) is shown in blue, and the E' domain (top) is shown in red. The view of the structure shown to the right is a 90° rotation of the left view. β strands are numbered according to the order in which they occur in the primary sequence of the individual domains (Figure 1). Cysteine linkages are annotated with their residue numbers; a correlation with cysteine numbering within each of the 2 domains can be found in Figure 1.




Figure 5. Pico-to-microsecond and millisecond structural dynamics of TIL'E'. (A) Backbone TIL'E' $\{^1\text{H}\}^{15}\text{N}$ heteronuclear NOEs that report on motions on the subnanosecond timescale. Low values indicate flexible, unstructured regions, whereas stabilizing structural elements give rise to higher hetNOEs. Secondary-structure elements of TIL'E' are depicted below the plot. (B) Simultaneous stereo representation of the structure and pico-to-microsecond dynamics (gray) overlaid with the lowest-energy structure from the single-structure calculations (TIL', blue; E', red). The stereo mode is wall-eye. (C) Nitrogen backbone millisecond chemical

β strand) and lack of a significant hydrophobic core, such that 5 conserved disulfide bonds constitute the major stabilizing force constraining the fold (Figure 4). TIL' is formed of 2 short β sheets, $\beta 1:\beta 2$ (residues 772-775:806-809) and $\beta 3:\beta 4$ (residues 814-817:820-823), that form a scaffold bearing a long 30-residue loop, the $\beta 1$ -to- $\beta 2$ loop. This loop encompasses an 8-residue insertion between the second and third conserved TIL' cysteine residues as compared with structural homologs of TIL' (supplemental Figure 1). The second antiparallel β sheet, formed of strands $\beta 3$ and $\beta 4$, is connected by a reverse turn forming a small-hairpin structure. There is a single turn of a 3_{10} helix (residues 824-826) at the C terminus of TIL'. TIL' belongs to the *Ascaris* protease inhibitor family, defined by a 10-cysteine signature and a conserved protein fold,³³ with the closest structural homolog being a chymotrypsin inhibitor domain (Protein Data Bank accession number ICCV) with a Z score of 3.6, as calculated by the DALI server.³⁴ In contrast, Figure 4 shows that the greater proportion of E' is formed of a triple-stranded antiparallel β sheet formed of strands $\beta 3$ (residues 839-844), $\beta 4$ (residues 847-852), and $\beta 5$ (residues 855-858). Additionally, the N terminus contains a short double-stranded $\beta 1:\beta 2$ sheet (residues 829-831:834-836). The relative positions of the 2 β sheets are restrained by the E' Cys829-Cys851 disulfide bond. The 6-cysteine E' domain was previously suggested to be a member of the fibronectin I-like superfamily of proteins³⁵ and thus similar to the von Willebrand factor type C (VWC) module. Supplemental Figure 8 shows an overlay of the structure of the E' domain solved here by NMR spectroscopy and the first subdomain of a full VWC module. The 2 domains shown are structurally highly similar with a backbone root-mean-square deviation (RMSD) of 1.3 Å, thus highlighting the structural similarities between the E' domain and the VWC module.

The family of the 10 lowest-energy structures of TIL'E' is well defined, with an average backbone pairwise RMSD of 1.12 Å, and corresponding RMSDs for the TIL' and E' domains in isolation of 1.37 Å and 0.34 Å, respectively (supplemental Figure 9). The backbone RMSD of the TIL' domain excluding the long $\beta 1$ -to- $\beta 2$ loop is 0.81 Å, indicating that this loop dominates the structural heterogeneity of TIL' and alluding to its intrinsic dynamic character (supplemental Figure 10). The 10 lowest-energy structures have 73.1% of residues in the most-favored regions in the Ramachandran plot, 22.3% in the additionally allowed regions, 3.4% in the generously allowed regions, and 1.2% in disallowed regions.

TIL' is strikingly dynamic on at least 2 timescales

The conformational sampling of a protein is often essential to its biological activity,³⁶ and hence the dynamic characterization of TIL'E' is of great importance for elucidating the mechanism by which FVIII is stabilized in plasma. The structural dynamics of TIL'E' were quantified experimentally by ^{15}N nuclear spin relaxation experiments.¹⁷ Analysis

Figure 5 (continued) exchange contributions, $R_{\text{ex}} = R_2^{\text{eff}}(25 \text{ Hz}) - R_2^{\text{eff}}(1000 \text{ Hz})$, obtained at 700 MHz. Significant exchange contributions, R_{ex} , indicate dynamics on a microsecond to millisecond timescale (conformational exchange). Backbone millisecond dynamics are almost entirely confined to the TIL' domain, with the E' domain comparatively rigid on this timescale. (D) Combined dynamics of TIL'E'; orange balls represent residues with $\{^1\text{H}\}^{15}\text{N}$ NOE < 0.6 , whereas the backbone ribbon is colored red (blue) for residues whose R_{ex} is greater (less) than 1.5 s^{-1} . The backbone for residues where no R_{ex} is available is colored gray. (E) Two representative dispersion profiles of residues with millisecond structural dynamics, Cys776 and Ser806. Points (vertical bars) represent measured R_{ex} values (uncertainties), and the full-drawn line is a least-squares fit of a 2-site conformational exchange model to the data shown (red, 700 MHz; black, 500 MHz).

of these relaxation data revealed interesting motional trends; most notably, that there is a distinguishable mobility differential between the TIL' and E' domains. $\{^1\text{H}\}^{15}\text{N}$ nuclear Overhauser effects (hetNOEs; Figure 5A), which report specifically on backbone fluctuations on a pico-to-nanosecond (ps-ns) timescale, clearly show that, with the exception of the very C-terminal residues, the E' domain is rigid with a uniform distribution of hetNOE values around 0.7. In contrast, several residues in the $\beta 1$ -to- $\beta 2$ loop of the TIL' domain show significantly lower NOE values, indicating a comparatively higher degree of flexibility. The amplitudes of the local ps-ns motions were quantified as squared order parameters,¹⁸ S^2 , according to the model-free analysis of the ^{15}N spin relaxation rates (supplemental Table 4), and confirmed the relative flexibility of the TIL' $\beta 1$ -to- $\beta 2$ loop on this timescale.³⁷ The analysis of the ^{15}N relaxation rates includes a determination of the diffusion tensor, D . Of special interest here is the ratio of the parallel and the perpendicular components of the axial diffusion tensor, D_{\parallel}/D_{\perp} , because this ratio reports on the shape of the molecule. Firstly, the ratios obtained separately for the 2 domains are very similar ($D_{\parallel,\text{TIL}'}/D_{\perp,\text{TIL}'} = 1.82 \pm 0.05$ and $D_{\parallel,\text{E}'}/D_{\perp,\text{E}'} = 1.9 \pm 0.1$), which indicates that the TIL' and E' domains tumble as a single entity with only limited interdomain motion. Secondly, the relatively large values of D_{\parallel}/D_{\perp} confirm that the overall structure is a highly prolate spheroid, in agreement with the calculated structures (Figure 4).

Backbone dynamics on the broader pico-to-microsecond (ps- μs) timescale were investigated, because ligand binding and dissociation often takes place in this time regime.^{36,38} The amplitudes of motions over the ps- μs timescale were estimated from backbone chemical shifts³¹ and subsequently included in structure calculations,^{21,39} together with the restraints listed above, to determine an ensemble of protein conformations that represent, simultaneously, the TIL'E' structure and its associated dynamics. Accordingly, this structural ensemble represents a more faithful atomistic description of the conformational variability of TIL'E' on a ps- μs timescale. The ensemble representation of TIL'E' was systematically cross-validated by a combination of RDCs and side-chain ^{13}C methyl chemical shifts⁴⁰⁻⁴³ to give an optimal ensemble size of 10 replicas (supplemental Figure 11). The ensemble representation is shown in Figure 5B and shows that the $\beta 1$ -to- $\beta 2$ loop is significantly more flexible than the remainder of TIL'E'.

Although the hetNOEs (Figure 5A) and chemical shifts report on ps-ns and ps- μs dynamics, respectively, structural dynamics on the millisecond timescale can be specifically probed using CPMG relaxation dispersion experiments.^{19,44} The time constants of many biochemical processes, such as ligand binding and dissociation,³⁶ are on the millisecond timescale, and CPMG experiments were therefore performed on the TIL'E' domains to quantify such dynamics (Figure 5C). A first inspection of the CPMG data reveals localization of slower motions to the domain TIL', particularly in the $\beta 1$ -to- $\beta 2$ loop (Figure 5C), confirming the existence of a sparsely populated (excited) state with a lifetime in the millisecond range, whereas the E' domain remains rigid on this timescale. A detailed analysis of the CPMG relaxation dispersions reveals that the ground state of TIL'E' exchanges with an excited state; the lifetime of the excited state is approximately 0.5 ms and has a population of 3.5% (supplemental Methods and materials). Excited states often have significant functional roles in molecular recognition and ligand binding, and the existence of the TIL'E' excited state is likely to be functionally relevant for the binding of VWF to FVIII.

A summary of the TIL'E' dynamics is shown in Figure 5D, from which it is evident that the TIL' $\beta 1$ -to- $\beta 2$ loop is strikingly dynamic on at least 2 timescales, whereas the remainder of TIL'E'




Figure 6. Structural interpretation of type 2N VWD mutations. (A) Ribbon diagram showing the position of the reported TIL'E' type 2N missense mutations. Noncysteine mutations are shown with green spheres, and those involving cysteine residues are colored black. The TIL' domain is colored blue, and the E' domain colored red. A wall-eye stereo view is shown in supplemental Figure 12. (B) Surface representation of TIL'E' with the type 2N noncysteine mutations colored green, and those involving cysteine residues colored black. The surface of the TIL' domain is shown with a light-blue color, and the surface of the E' domain is shown with a light-red color. (C) Electrostatic surface potential of TIL'E', with blue (red) indicating positive (negative) charge. The view on the left side shows the region of concentrated positive charge density, circumscribed by a yellow dashed line, which is the putative binding site for the $\alpha 3$ domain of the FVIII light chain. The views on the right side of all panels are a 180° rotation of the views shown on the left.

Table 1. Type 2N missense mutations in domains TIL' and E' of VWF

Domain	Mutation	Δ Volume (\AA^3)*	Position	Predicted effect
TIL'	R782W	+41.1	β 1- β 2 loop	Loss +ve, polar-to-hydrophobic, structural perturbation
	G785E	+88.1	β 1- β 2 loop	Introduce -ve charge, \uparrow volume
	E787K	+8.9	β 1- β 2 loop	Introduce +ve in region of -ve charge, highly deleterious
	C788R	+94.7	β 1- β 2 loop	Introduction of -SH, introduce +ve, \uparrow volume
	C788Y	+108.4	β 1- β 2 loop	Introduction of -SH, \uparrow volume
	T789P	-3.6	β 1- β 2 loop	Perturbation of putative a3 binding region
	T791M	+40.9	β 1- β 2 loop	Perturbation of putative a3 binding region
	Y795C	-96.4	β 1- β 2 loop	Exposed -SH
	M800V	-28.5	β 1- β 2 loop	Border of putative a3 binding region
	C804F	+85.4	β 1- β 2 loop	Introduction of -SH
	P812L	+41.0	β 2- β 3 loop	Perturbation of putative a3 binding region
	R816W	+42.1	β 3	Loss of conserved +ve in putative a3 binding region
	R816Q	-40.7	β 3	Loss of conserved +ve in putative a3 binding region
	H817Q	-7.8	β 3	Loss of conserved +ve in putative a3 binding region
E'	R854W	+42.1	β 4- β 5 loop	Loss +ve, polar-to-hydrophobic
	R854Q	-40.7	β 4- β 5 loop	Loss +ve
	C858F	+97.4	β 5	Introduction of -SH
	C858S	-0.4	β 5	Introduction of -SH

*Changes in residue volumes are based on Pontius et al.⁴⁷

provides a rigid scaffold supporting this conformationally dynamic entity.

Discussion

The solution structure and dynamic characterization of TIL'E' allow an unprecedented interpretation of the likely functional consequence of type 2N VWD missense mutations. The greater proportion of the known type 2N missense mutations are distributed in the vicinity of the dynamic TIL' β 1-to- β 2 loop (Figure 6A). Type 2N mutations that involve a cysteine residue (C788R/Y, Y795C, and C804F in TIL'; C858S/F in E') are associated with aberrant multimerization, poor secretion, and reduced FVIII binding,⁴⁵ indicating that correct disulfide-bond formation is critical to the folding and function of VWF (Figure 3). Of the type 2N mutations, 3 account for the majority of cases reported (T791M, R816W, and R854Q),¹⁰ of which R854Q occurs with polymorphic frequency,⁴ and all of which are in immediate proximity to the β 1-to- β 2 loop. However, the most accurate reporters of the FVIII binding site are those mutations that are associated with a more severe type 2N phenotype; that is, E787K, T791M, and R816W.¹⁰ Two of these mutations, T791M and R816W, together with T789P, M800V, R816Q, and H817Q, are clustered around a region of positive charge density on TIL' (Figure 6B-C). Two regions on the FVIII light chain have been implicated in binding VWF, that is, the N-terminal acidic a3 domain and the C-terminal C2 domain. Although these 2 regions are thought to act synergistically in binding VWF, studies show that a3 in isolation binds ~8 times more strongly to VWF than the C2 domain, with affinities of ~72 nM and 564 nM,⁴⁶ respectively, and the acidic a3 domain is critical to high-affinity binding to VWF.⁴⁶ We therefore hypothesize that the positively charged and dynamic region on TIL'E' is the major binding site to the negatively charged FVIII a3 domain. Thus, the deleterious effect of the R816W mutant is likely due to the introduction of a large and hydrophobic side chain and/or loss of positive charge (Table 1⁴⁷). Figure 6 shows that residues R782, G785, and E787 are on the opposite side of the structure yet in close proximity to the β 1-to- β 2 loop (Figure 6 and supplemental Figure 12), which suggests that the severe type 2N mutation

E787K, and mutations R782W and G785E, lead to deficiencies in FVIII binding through a perturbation of the β 1-to- β 2 loop, the upper portion of which borders the predicted binding region.

In summary, the majority of the noncysteine type 2N mutations (Figure 6) are found in the vicinity of the flexible regions of TIL', thereby localizing the FVIII binding site to this part of the VWF protein. Of the type 2N mutations in TIL'E' involving charged residues, all but one result in loss of positive charge, supporting a predominantly electrostatic interaction between VWF and the FVIII light chain, which is in agreement with the fact that high ionic strength and low pH result in a much lower affinity of the VWF-FVIII complex.^{27,48} Hence, based on the foregoing analyses, we propose that E' and the β sheets of TIL' provide a rigid scaffold for the positively charged region on TIL', which complements the charge distribution of the FVIII light chain to electrostatically guide VWF-FVIII complex formation.

The cysteine-rich N- and C-terminal flanking regions of VWF have been the subject of significant efforts aimed at characterizing the structure and plasticity of function of this unique protein. Superposition of the VWD type 2N missense mutations on the structure of TIL'E', together with the characterization of its structural dynamics, reveals the malleable FVIII binding surface of VWF and represents an important step toward a detailed molecular understanding of these functionally important VWF domains for which atomic-resolution structures have hitherto been unavailable.

Acknowledgments

The authors thank Dr P. J. Lenting for providing the mAb-418, A. Riddell for helpful discussions and for providing the recombinant FVIII, and Prof S. K. Srai, Dr K. Gomez, and Prof G. Waksman for helpful discussions. The authors acknowledge the Medical Research Council and the National Institute for Medical Research for access to the 800 MHz spectrometer for exploratory characterizations of TIL'E'.

This work was supported by the *International Journal of Experimental Pathology* and the Comprehensive Biomedical Research Centre (studentship to N.S.), the Rosetrees Trust, Novo

Nordisk A/S, and the Biotechnology and Biological Sciences Research Council (BBSRC).

Authorship

Contribution: N.S., E.G.D.T., and D.F.H. designed the research; N.S., J.K., and D.F.H. performed and analyzed the NMR experiments and NMR data; N.S. and D.F.H. performed structure calculations; N.S. and L.D.C. cloned, expressed, and purified isotope-labeled TIL/E'; N.S. and L.D.C. designed and performed dot-blot analyses;

K.T. performed MS studies; T.A.J.M. performed solid-phase binding assays; and all authors discussed the results and contributed to writing the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: D. Flemming Hansen, Institute of Structural and Molecular Biology, University College London, Gower St, London, WC1E 6BT, United Kingdom; e-mail: d.hansen@ucl.ac.uk; or Edward G. D. Tuddenham, The Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Hospital NHS Trust, Pond St, London, NW3 2QG, United Kingdom; e-mail: e.tuddenham@ucl.ac.uk.

References

- Tuddenham EG, Lane RS, Rotblat F, et al. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. *Br J Haematol*. 1982;52(2):259-267.
- Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. *J Clin Invest*. 1977;60(2):390-404.
- Sadler JE. Biochemistry and genetics of von Willebrand factor. *Annu Rev Biochem*. 1998; 67(1):395-424.
- Goodeve AC. The genetic basis of von Willebrand disease. *Blood Rev*. 2010;24(3):123-134.
- Zhou Y-F, Eng ET, Nishida N, Lu C, Walz T, Springer TA. A pH-regulated dimeric bouquet in the structure of von Willebrand factor. *EMBO J*. 2011;30(19):4098-4111.
- Zhang Q, Zhou Y-F, Zhang C-Z, Zhang X, Lu C, Springer TA. Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. *Proc Natl Acad Sci USA*. 2009;106(23):9226-9231.
- Brondijk THC, Bihan D, Farndale RW, Huizinga EG. Implications for collagen I chain registry from the structure of the collagen von Willebrand factor A3 domain complex. *Proc Natl Acad Sci USA*. 2012;109(14):5253-5258.
- Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. *J Biol Chem*. 1987;262(18):8443-8446.
- Zhou Y-F, Eng ET, Zhu J, Lu C, Walz T, Springer TA. Sequence and structure relationships within von Willebrand factor. *Blood*. 2012;120(2): 449-458.
- Hampshire DJ, Goodeve AC. The international society on thrombosis and haemostasis von Willebrand disease database: an update. *Semin Thromb Hemost*. 2011;37(5):470-479.
- Piétu G, Ribba AS, Chérel G, et al. Epitope mapping of inhibitory monoclonal antibodies to human von Willebrand factor by using recombinant cDNA libraries. *Thromb Haemost*. 1994;71(6):788-792.
- Jorieux S, Gaucher C, Piétu G, Chérel G, Meyer D, Mazurier C. Fine epitope mapping of monoclonal antibodies to the NH2-terminal part of von Willebrand factor (VWF) by using recombinant and synthetic peptides: interest for the localization of the factor VIII binding domain. *Br J Haematol*. 1994;87(1):113-118.
- Lobstein J, Emrich CA, Jeans C, Faulkner M, Riggs P, Berkmen M, SHuffle, a novel *Escherichia coli* protein expression strain capable of correctly folding disulfide bonded proteins in its cytoplasm. *Microb Cell Fact*. 2012;11(1):56.
- Hansen MR, Mueller L, Pardi A. Tunable alignment of macromolecules by filamentous phage yields dipolar coupling interactions. *Nat Struct Biol*. 1998;5(12):1065-1074.
- Ruckert M, Otting G. Alignment of biological macromolecules in novel nonionic liquid crystalline media for NMR experiments. *J Am Chem Soc*. 2000;122:7793-7797.
- Pringle SD, Giles K, Wildgoose JL, et al. An investigation of the mobility separation of some peptide and protein ions using a new hybrid quadrupole/travelling wave IMS/OA-TOF instrument. *Int J Mass Spectrom*. 2007;261(1): 1-12.
- Kay LE, Torchia DA, Bax A. Backbone dynamics of proteins as studied by 15N inverse detected heteronuclear NMR spectroscopy: application to staphylococcal nuclease. *Biochemistry*. 1989; 28(23):8972-8979.
- Lipari G, Szabo A. Model-free approach to the interpretation of nuclear magnetic-resonance relaxation in macromolecules.1. theory and range of validity. *J Am Chem Soc*. 1982;104(17): 4546-4559.
- Vallurupalli P, Hansen DF, Stoller E, Meirovitch E, Kay LE. Measurement of bond vector orientations in invisible excited states of proteins. *Proc Natl Acad Sci USA*. 2007;104(47):18473-18477.
- Herrmann T, Güntert P, Wüthrich K. Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion angle dynamics algorithm DYANA. *J Mol Biol*. 2002;319(1):209-227.
- Schwieters C, Kuszewski J, Mariusclore G. Using Xplor-NIH for NMR molecular structure determination. *Prog Nucl Magn Reson Spectrosc*. 2006;48(1):47-62.
- Marti T, Rösselet SJ, Titani K, Walsh KA. Identification of disulfide-bridged substructures within human von Willebrand factor. *Biochemistry*. 1987;26(25):8099-8109.
- Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. *Proc Natl Acad Sci USA*. 1992;89(8):3531-3535.
- Casonato A, Pontara E, Zerbinati P, Zucchetto A, Girolami A. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications. *Am J Clin Pathol*. 1998;109(3): 347-352.
- Saenko EL, Scandella D. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. *J Biol Chem*. 1995;270(23): 13826-13833.
- Saenko EL, Loster K, Josic D, Sarafanov AG. Effect of von Willebrand Factor and its proteolytic fragments on kinetics of interaction between the light and heavy chains of human factor VIII. *Thromb Res*. 1999;96(5):343-354.
- Dimitrov JD, Christophe OD, Kang J, et al. Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor. *Biochemistry*. 2012;51(20):4108-4116.
- Montelione GT, Lyons BA, Emerson SD, Tashiro M. An efficient triple resonance experiment using carbon-13 isotropic mixing for determining sequence-specific resonance assignments of isotopically-enriched proteins. *J Am Chem Soc*. 1992;114:10974-10975.
- Grzesiek S, Anglister J, Bax A. Correlation of backbone amide and aliphatic side-chain resonances in 13C/15N enriched proteins by isotropic mixing of 13C magnetization. *J Magn Reson B*. 1993;101:114-119.
- Kay LE, Xu G-Y, Singer AU, Muhandiram DR, Forman-Kay JD. A gradient enhanced HCCH-TOCSY experiment for recording side-chain 1H and 13C correlations in H2O samples of proteins. *J Magn Reson B*. 1993;101: 333-337.
- Shen Y, Delaglio F, Cornilescu G, Bax A. TALOS+: a hybrid method for predicting protein backbone torsion angles from NMR chemical shifts. *J Biomol NMR*. 2009;44(4): 213-223.
- Bax A, Kontaxis G, Tjandra N. Dipolar couplings in macromolecular structure determination. *Methods Enzymol*. 1997; 2001(339):127-174.
- Rawlings ND, Tolle DP, Barrett AJ. Evolutionary families of peptidase inhibitors. *Biochem J*. 2004; 378(Pt 3):705-716.
- Holm L, Rosenström P. Dali server: conservation mapping in 3D. *Nucleic Acids Res*. 2010;38(Web Server issue):W545-9.
- O'Leary JM, Hamilton JM, Deane CM, Valeev NV, Sandell LJ, Downing AK. Solution structure and dynamics of a prototypical chordin-like cysteine-rich repeat (von Willebrand Factor type C module) from collagen IIA. *J Biol Chem*. 2004; 279(51):53857-53866.
- Henzler-Wildman K, Kern D. Dynamic personalities of proteins. *Nature*. 2007;450(7172): 964-972.
- Yang D, Mok Y-K, Forman-Kay JD, Farrow NA, Kay LE. Contributions to protein entropy and heat capacity from bond vector motions measured by NMR spin relaxation. *J Mol Biol*. 1997;272(5): 790-804.
- Lange OF, Lakomek NA, Farès C, et al. Recognition dynamics up to microseconds revealed from an RDC-derived ubiquitin ensemble in solution. *Science*. 2008; 320(5882):1471-1475.
- Lindorff-Larsen K, Best RB, Depristo MA, Dobson CM, Vendruscolo M. Simultaneous determination of protein structure and dynamics. *Nature*. 2005; 433(7022):128-132.

40. Hansen DF, Neudecker P, Vallurupalli P, Mulder FAA, Kay LE. Determination of Leu side-chain conformations in excited protein states by NMR relaxation dispersion. *J Am Chem Soc.* 2010; 132(1):42-43.
41. Hansen DF, Neudecker P, Kay LE. Determination of isoleucine side-chain conformations in ground and excited states of proteins from chemical shifts. *J Am Chem Soc.* 2010;132(22):7589-7591.
42. Hansen DF, Kay LE. Determining valine side-chain rotamer conformations in proteins from methyl ¹³C chemical shifts: application to the 360 kDa half-proteasome. *J Am Chem Soc.* 2011; 133(21):8272-8281.
43. Mulder FAA. Leucine side-chain conformation and dynamics in proteins from ¹³C NMR chemical shifts. *ChemBioChem.* 2009;10(9): 1477-1479.
44. Palmer AG III, Kroenke CD, Loria JP. Nuclear magnetic resonance methods for quantifying microsecond-to-millisecond motions in biological macromolecules. *Methods Enzymol.* 2001;339: 204-238.
45. Allen S, Abuzenadah AM, Blagg JL, et al. Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. *Blood.* 2000;95(6): 2000-2007.
46. Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor. *J Biol Chem.* 1997;272(29): 18007-18014.
47. Pontius J, Richelle J, Wodak SJ. Deviations from standard atomic volumes as a quality measure for protein crystal structures. *J Mol Biol.* 1996;264(1): 121-136.
48. Cooper HA, Griggs TR, Wagner RH. Factor VIII recombination after dissociation by CaCl₂. *Proc Natl Acad Sci USA.* 1973;70(8): 2326-2329.